Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

More To FDA AdComm Selection Process Than Meets The Eye

This article was originally published in The Gray Sheet

Executive Summary

FDA issued a draft guidance on how it addresses "appearance issues" when it comes to reviewing conflicts of interest in prospective members of an advisory committee. The agency says the guidelines are needed due to a general lack of understanding about how FDA selects and evaluates members of its panels, and how it grants waivers to participate.

Advertisement

Related Content

With Five Guidances, FDA Overhauls Its Advisory Committee Policies

Topics

Advertisement
UsernamePublicRestriction

Register